Drug Approval | September 16, 2025
The products include high-quality, advanced anti-infective formulations such as EMROK (Levonadifloxacin) and MIQNAF (Nafithromycin)
Four FDA-approved products strengthen portfolio and reaffirm commitment to global reach
Products manufactured at the new Vaughan facility will support research in areas including cancer, infectious disease, mental health, and environmental safety
The facility has been designed with a dual focus on efficiency and sustainability
These licenses are given in areas of infectious disease diagnostics, immunodiagnostics, and vaccine development
Edwards’ latest-generation balloon-expandable transcatheter heart valve incorporates a proprietary calcification-resistant tissue technology
RTX001 represents a groundbreaking advance in the treatment of end-stage liver disease, offering new hope for patients with limited options
The positive benefit-risk profile of vericiguat in its approved indication in patients with HFrEF following a recent heart failure event based on the pivotal Phase III VICTORIA trial remains unchanged
The sudden subsequent decision to suspend IXCHIQ is based on updated VAERS data
Subscribe To Our Newsletter & Stay Updated
